Who are Fosfomycin sodium intravenous's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fosfomycin Oral Suspension, Delamanid in Oral Dosage Form, Delamanid (DLM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fosfomycin-sodium-intravenous.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fosfomycin sodium intravenous — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fosfomycin sodium intravenous (Fosfomycin sodium intravenous) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell wall synthesis inhibitor. Area: Infectious Disease.

phase 3 Cell wall synthesis inhibitor MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Fosfomycin sodium intravenous (Fosfomycin sodium intravenous) — Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Fosfomycin inhibits bacterial cell wall synthesis by inactivating the MurA enzyme, preventing peptidoglycan cross-linking.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fosfomycin sodium intravenous TARGET	Fosfomycin sodium intravenous	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	phase 3	Cell wall synthesis inhibitor	MurA (UDP-N-acetylglucosamine enolpyruvyl transferase)
Fosfomycin Oral Suspension	Fosfomycin Oral Suspension	Public Health Service of Amsterdam	marketed	Cell wall synthesis inhibitor	MurA (enolpyruvate transferase)
Delamanid in Oral Dosage Form	Delamanid in Oral Dosage Form	Wits Health Consortium (Pty) Ltd	phase 3	Mycobacterial cell wall synthesis inhibitor	DprE1 (decaprenylphosphoryl-arabinose-1-phosphatase)
Delamanid (DLM)	Delamanid (DLM)	Wuhan Pulmonary Hospital	phase 3	Mycobacterial cell wall synthesis inhibitor	DprE1 (decaprenylphosphoryl-β-D-ribose 2'-epimerase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell wall synthesis inhibitor class)

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 drug in this class
Public Health Service of Amsterdam · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fosfomycin sodium intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/fosfomycin-sodium-intravenous. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab